Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser1177/Thr497 of endothelial nitric oxide synthase in diabetic mice

Table 1 General characteristics

			C57BL6J-Vehicle			KKAy-Vehicle				KKAy-Candesartan					KKAy-Azilsartan
Number				7			9				9				8
Body weight
	baseline	(g)	22.4	±	0.4	36.5	±	1.3		37.2	±	1.6		37.0	±	1.6
	1 week	(g)	23.9	±	0.6	41.2	±	0.8	††	40.8	±	0.9	††	41.3	±	0.9	††
	2 week	(g)	24.3	±	0.6	40.5	±	0.7	††	40.5	±	0.9	††	40.6	±	0.9	††
	3 week	(g)	25.1	±	0.8	43.8	±	0.6	††	43.1	±	0.9	††	43.0	±	0.8	††
Systolic blood pressure
	baseline	(mmHg)	101	±	1	101	±	3		100	±	2		102	±	2
	1 week	(mmHg)	100	±	2	109	±	2	†	82	±	3	**	84	±	3	**
	2 week	(mmHg)	102	±	1	104	±	2		81	±	2	**	82	±	2	**
	3 week	(mmHg)	99	±	2	108	±	2	†	79	±	2	**	82	±	3	**
Fasting blood glucose
	baseline	(mg/dL)	53	±	4	75	±	21		78	±	8		77	±	7
	2 week	(mg/dL)	63	±	4	139	±	22	†	104	±	10	†	138	±	14	†
Plasma uric acid
	3 week	(μmol/L)	6.5	±	1.8	18.7	±	1.5	†	18.4	±	3.0	†	18.0	±	2.5	†
Tissue weight (g/g)
subcutaneous fat/body weight			0.015	±	0.002	0.040	±	0.001	††	0.038	±	0.002	††	0.042	±	0.001	††
visceral fat/body weight			0.014	±	0.001	0.025	±	0.001	††	0.024	±	0.001	††	0.028	±	0.001	††
liver/body weight			0.047	±	0.002	0.064	±	0.002	††	0.058	±	0.002	††	0.066	±	0.001	††
soleus muscle/body weight			0.013	±	0.000	0.008	±	0.000	††	0.009	±	0.000	††	0.007	±	0.000	††
quadriceps muscle/body weight			0.014	±	0.001	0.009	±	0.000	††	0.010	±	0.000	††	0.009	±	0.000	††

Values are mean ± SEM. **p<0.01 vs KKAy-Vehicle. † p<0.05 and †† p<0.01 vs C57BL6J-Vehicle.

ISSN: 1475-2840